Crohn's disease -; an autoimmune disorder -; is characterized by chronic inflammation of the digestive tract, resulting in a slew of debilitating gastrointestinal symptoms that vary from patient to ...

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic ...

The Company is also pleased to announce the closing of the first tranche of the Offering for gross proceeds of $1,610,147.55 from the issuance of 2,927,541 Units. All securities issued pursuant to the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral ...

CereVasc shared data from a study demonstrating that its eShunt system may help deliver gene therapies to the central nervous ...

UC San Diego researchers discover two distinct molecular subtypes of Crohn’s disease using patient-derived organoids, opening ...

RNA-based drugs have the potential to change the standard of care for many diseases, making personalized medicine a reality.

Phare Bio, along with the Collins Lab at the Massachusetts Institute of Technology (MIT) and Harvard's Wyss Institute, today ...

The Orphan Drug designation is supported by positive preclinical data from bleomycin-induced mouse models and patient-derived skin fibroblasts.

Stimulating a key metabolic pathway in T cells can make them work more effectively against tumors when combined with immune ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing ...